NeoVax(MI) vaccine developed by Dana-Farber Cancer Institute could be approved soon with promising results in boosting immune response in melanoma patients
Lara Maior
Health
Vyacheslav Lopatin / Alamy / Profimedia
Always see our news on Google
The clinical trial of the personalized vaccine NeoVax(MI) has shown promising results in the treatment of melanoma, generating a strong immune response. The vaccine contains patient-specific neoantigens and is administered together with standard immunotherapies such as nivolumab and ipilimumab. Scientists observed an increase in immune cells after vaccination, indicating effective immune activation. This innovative approach could significantly improve treatments for skin cancer.
Sources
Vaccinul contra unui tip agresiv de cancer, la un pas de a intra pe piață. Rezultatele remarcabile dau speranțe pacienților
Consiliul Concurenței analizează tranzacţia prin care Mehiläinen Oy preia rețeaua de centre mediale Regina Maria
Consiliul Concurenţei analizează preluarea Grupului Regina Maria de către Mehiläinen Oy
Latest News
15:48
Turkish commercial ships attacked with drones in the Black Sea. Ankara condemns the incidents.
15:45
The Ministry of Finance is preparing for the Moody's evaluation, after maintaining the rating from Fitch.
15:39
A 70-year-old man died after being hit by a car on Calea Dorobanți in Bucharest.
15:30
Mihai Stoica, the president of FCSB, announces that the team will bring in a new foreign striker after being eliminated from the Conference League
15:28
Fire on board a vessel with migrants in the English Channel: 157 people rescued by the French Coast Guard
See more news
NEWS ON THE SAME TOPICS
.webp)
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
